What is Rectify Pharmaceuticals?
Rectify Pharmaceuticals is a biotechnology innovator headquartered in Cambridge, Massachusetts, dedicated to the development of Positive Functional Modulators (PFMs). The company focuses on precision therapeutics designed to restore the function of ABC transporters, which are essential for cellular health. By targeting the underlying mechanisms of serious genetic diseases, Rectify aims to provide disease-modifying treatments that address the root causes of patient pathology rather than merely managing symptoms. Its market position is defined by a commitment to high-impact science and the translation of complex biological insights into viable, life-changing medical interventions.
How much funding has Rectify Pharmaceuticals raised?
Rectify Pharmaceuticals has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2021): $100M with participation from Forbion, Atlas Venture, and Omega Fund Management
Key Investors in Rectify Pharmaceuticals
Forbion
Forbion is a global life sciences venture capital firm that specializes in guiding biotech and biopharmaceutical companies from early-stage research through clinical development.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Omega Fund Management
Omega Fund Management is a specialized investment firm that focuses on identifying and supporting high-growth companies within the life sciences and biotechnology sectors.
What's next for Rectify Pharmaceuticals?
With the recent influx of capital, Rectify Pharmaceuticals is expected to prioritize the expansion of its clinical development infrastructure and the advancement of its PFM platform. The company will likely focus on scaling its internal research capabilities and strengthening its intellectual property portfolio to maintain a competitive edge in the precision medicine sector. Future strategic initiatives will likely involve deepening partnerships with academic institutions and clinical research organizations to expedite the transition of its lead assets into human trials. As the firm matures, the focus will shift toward demonstrating the safety and efficacy of its therapeutic modalities, setting the stage for potential long-term commercialization and further institutional support.
See full Rectify Pharmaceuticals company page
